Genomic aberrations of the PTEN tumour suppressor gene are among the most common in
prostate cancer. Inactivation of PTEN by deletion or mutation is identified in∼ 20% of …

Prostate cancer is the most commonly diagnosed cancer affecting men in the United States.
The prostate is a hormone-dependent gland in which androgen hormones testosterone and …

While mutations affecting protein-coding regions have been examined across many
cancers, structural variants at the genome-wide level are still poorly defined. Through …

An increasingly recognized resistance mechanism to androgen receptor (AR)-directed
therapy in prostate cancer involves epithelial plasticity, in which tumor cells demonstrate low …

Background Prostate cancer is a heterogeneous disease, but current treatments are not
based on molecular stratification. We hypothesized that metastatic, castration-resistant …

Toward development of a precision medicine framework for metastatic, castration-resistant
prostate cancer (mCRPC), we established a multi-institutional clinical sequencing …

Over the past 20 years, there has been considerable progress in our understanding of the
biological functions of the BRCA1 and BRCA2 cancer susceptibility genes. This has led to …

During the past 10 years, preclinical studies implicating sustained androgen receptor (AR)
signalling as the primary driver of castration-resistant prostate cancer (CRPC) have led to …

The success of next-generation androgen receptor (AR) pathway inhibitors, such as
abiraterone acetate and enzalutamide, in treating prostate cancer has been hampered by …

Of late, targeted protein degradation (TPD) has surfaced as a novel and innovative chemical
tool and therapeutic modality. By co-opting protein degradation pathways, TPD facilitates …